PE20211410A1 - Formas farmaceuticas orales biodisponibles - Google Patents

Formas farmaceuticas orales biodisponibles

Info

Publication number
PE20211410A1
PE20211410A1 PE2021000157A PE2021000157A PE20211410A1 PE 20211410 A1 PE20211410 A1 PE 20211410A1 PE 2021000157 A PE2021000157 A PE 2021000157A PE 2021000157 A PE2021000157 A PE 2021000157A PE 20211410 A1 PE20211410 A1 PE 20211410A1
Authority
PE
Peru
Prior art keywords
oral pharmaceutical
pharmaceutical forms
available oral
solid dispersion
bio available
Prior art date
Application number
PE2021000157A
Other languages
English (en)
Inventor
Mandar V Dali
Akm Nasir Uddin
Original Assignee
Ptc Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ptc Therapeutics Inc filed Critical Ptc Therapeutics Inc
Publication of PE20211410A1 publication Critical patent/PE20211410A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se describen una forma de un compuesto lipofilo util en una composicion farmaceutica y un metodo para formar una dispersion solida, tal como un producto intermedio secado por pulverizacion, con la forma del compuesto. Tambien se describe el uso de la dispersion solida para proporcionar una forma farmaceutica oral biodisponible que tenga una mayor carga de dosis y una mejor disolucion menos sujeta a un efecto de la comida. Estas composiciones se emplean en el tratamiento de la leucemia, artritis reumatoide, esclerosis multiple, entre otras
PE2021000157A 2018-08-03 2019-08-02 Formas farmaceuticas orales biodisponibles PE20211410A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862714182P 2018-08-03 2018-08-03
PCT/US2019/044853 WO2020028778A1 (en) 2018-08-03 2019-08-02 Bioavailable oral dosage forms

Publications (1)

Publication Number Publication Date
PE20211410A1 true PE20211410A1 (es) 2021-08-02

Family

ID=67766269

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000157A PE20211410A1 (es) 2018-08-03 2019-08-02 Formas farmaceuticas orales biodisponibles

Country Status (23)

Country Link
US (1) US20210205225A1 (es)
EP (1) EP3829544A1 (es)
JP (1) JP2021532193A (es)
KR (1) KR20210041589A (es)
CN (1) CN112752570A (es)
AR (1) AR115913A1 (es)
AU (1) AU2019316036A1 (es)
BR (1) BR112021001859A2 (es)
CA (1) CA3107737A1 (es)
CL (1) CL2021000271A1 (es)
CO (1) CO2021001979A2 (es)
CR (1) CR20210093A (es)
EA (1) EA202190429A1 (es)
EC (1) ECSP21011795A (es)
IL (1) IL280471A (es)
MX (1) MX2021001364A (es)
NI (1) NI202100006A (es)
PE (1) PE20211410A1 (es)
PH (1) PH12021550237A1 (es)
SG (1) SG11202100984VA (es)
TN (1) TN2021000021A1 (es)
TW (1) TW202019414A (es)
WO (1) WO2020028778A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3080983C (en) 2009-05-27 2023-02-28 Pct Therapeutics, Inc. Method of inhibiting and reducing a viral infection
WO2019028171A1 (en) 2017-08-01 2019-02-07 Ptc Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
CN112028888B (zh) * 2020-09-11 2021-08-20 中国药科大学 一种化合物及其制备方法和用途
US20220151938A1 (en) * 2022-01-28 2022-05-19 Ptc Therapeutics, Inc. Tablet for use in treating huntington's disease and method of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526341A (ja) 2004-03-03 2007-09-13 スフェリックス， インコーポレイテッド 疎水性薬物のためのポリマー薬物送達システム
SG184755A1 (en) 2004-03-15 2012-10-30 Ptc Therapeutics Inc Carboline derivatives useful in the inhibition of angiogenesis
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
WO2008127714A1 (en) 2007-04-13 2008-10-23 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
WO2009040818A1 (en) 2007-09-25 2009-04-02 Solubest Ltd Compositions comprising lipophilic active compounds and method for their preparation
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
CA3080983C (en) * 2009-05-27 2023-02-28 Pct Therapeutics, Inc. Method of inhibiting and reducing a viral infection
WO2010138706A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
WO2017091373A1 (en) * 2015-11-25 2017-06-01 Patheon Development Services Inc. Amorphous dispersion granules and oral dosage forms

Also Published As

Publication number Publication date
WO2020028778A1 (en) 2020-02-06
EA202190429A1 (ru) 2021-06-15
CR20210093A (es) 2021-05-28
PH12021550237A1 (en) 2021-10-11
TW202019414A (zh) 2020-06-01
AU2019316036A1 (en) 2021-03-04
EP3829544A1 (en) 2021-06-09
SG11202100984VA (en) 2021-02-25
MX2021001364A (es) 2021-04-13
CO2021001979A2 (es) 2021-03-08
CN112752570A (zh) 2021-05-04
AR115913A1 (es) 2021-03-10
US20210205225A1 (en) 2021-07-08
NI202100006A (es) 2021-05-21
TN2021000021A1 (en) 2022-10-03
ECSP21011795A (es) 2021-03-31
IL280471A (en) 2021-03-25
BR112021001859A2 (pt) 2021-04-27
KR20210041589A (ko) 2021-04-15
CA3107737A1 (en) 2020-02-06
JP2021532193A (ja) 2021-11-25
CL2021000271A1 (es) 2021-08-20

Similar Documents

Publication Publication Date Title
PE20211410A1 (es) Formas farmaceuticas orales biodisponibles
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CL2017000287A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas.
DOP2018000297A (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
CL2015002145A1 (es) Preparación, usos y formas sólidas de ácido obeticólico (divisional de solicitud n° 3475-2014)
PE20180411A1 (es) Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina
GT201400043A (es) Imidazopiridazinas sustituidas con amino
NI201500118A (es) Imidazopiridazinas sustituidas
CL2018001686A1 (es) Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención (divisional solicitud 201701026)
UY36460A (es) Pirazolpiridinaminas
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
NI201600006A (es) Pirazolo-piridinaminas sustituidas
SV2018005713A (es) Compuestos de isoindol
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
DOP2016000118A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
DOP2016000268A (es) Compuestos de azol amido–sustituidos como inhibidores de tnks1 y/o tnks2
CL2018003418A1 (es) Formulaciones de óxido de polialquileno-asparaginasa y métodos de preparación y uso del mismo.
CO6300935A2 (es) Formulaciones orales e inyectables de compuestos de tetraciclina
EA201890929A1 (ru) Низкие дозировки композиций дипиридамола для перорального приема и их использование
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
AR114024A1 (es) Composición farmacéutica, dosis y tratamiento de la leucemia ph-positiva
MX2020004403A (es) Composiciones farmaceuticas que comprenden safinamida.
AR094934A1 (es) Imidazopiridazinas sustituidas
AR091835A1 (es) Una forma farmaceutica solida oral en dosis fija